Skip to content
AnalystLens

UNITEDHEALTH GROUP INC Annual Report, Year Ended Dec 31, 2000

Filing Date
Filed March 30, 2001
Period End
December 31, 2000
Security
UNH
In the record · 2016–202610-K1110-Q328-K173

UNH filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 173 current reports (8-K) between 2016 and 2026.

  1. FY2018 annual report10-K · Feb ’19Feb ’19
  2. Leadership change8-K · Feb ’22Feb ’22
  3. Leadership change8-K · Nov ’25Nov ’25

01—Abstract

Summary

Summary of the 10-K filed March 30, 2001. Cited figures are marked; the original filing is the authoritative source.

UnitedHealth Group (UNH) closed 2000 as its strongest year in company history, per management.

Revenues rose to a record $21.1 billiona (up 8% reported, roughly 12% in continuing markets after exiting certain Medicare and geographic markets). Earnings from operations reached $1.2 billion, up 27%, and net earnings were $736 million, or $2.19 diluted EPS (about $2.10 excluding a $14 million tax benefit and a $27 million gain tied to UnitedHealth Capital dispositions). Return on shareholders' equity rose to 19.0% from 14.1%, and operating cash flow exceeded $1.5 billion, up 28%.

Growth was broad across segments. Health Care Services (UnitedHealthcare and Ovations) grew revenue 6% to $18.7 billionb, with operating margin improving to 4.0%, driven by commercial premium yield gains and a lower commercial medical care ratio of 84.1%. Uniprise, Specialized Care Services and Ingenix grew revenue 15%, 34% and 45%, respectively.

The company also continued to shrink its Medicare footprint deliberately, with Medicare enrollment down 7%, and it is still completing its 1998 operational realignment, with $65 millionc of reserves remaining. Investors should weigh the risks the filing highlights. Medical costs are priced prospectively and margins are thin, so small changes in the medical care ratio can move results.

The company faces numerous class actions alleging ERISA and RICO violations, along with heavy government scrutiny of Medicare and FEHBP operations, although management does not expect a material adverse effect. Its AARP contract (about $3.5 billiond in annual premium) and Medicare operations remain concentration risks. Share repurchases of $1.2 billion in 2000 and a 2-for-1 split were executed, and the stock closed the year at $61.38, roughly 2.3 times its year-end 1999 level, as market capitalization reached $19.5 billion.

02—Key points

Key Highlights

  1. Record 2000 revenues of $21.1 billion, up 8% reported and about 12% in continuing markets.
  2. Earnings from operations rose 27% to $1.2 billion, with operating margin improving to 5.7% from 4.8%.
  3. Diluted EPS of $2.19 (about $2.10 excluding nonrecurring items), up roughly 32% from $1.60 in 1999 on a comparable basis; return on equity rose to 19.0% from 14.1%.
  4. Operating cash flow of $1.52 billion, up 28%, supporting $1.2 billion of share repurchases (31.0 million shares) in 2000.
  5. Health Care Services margin improved to 4.0%, with commercial medical care ratio falling to 84.1% from 84.6%.
  6. Specialized Care Services (+34%) and Ingenix (+45%) delivered strong revenue growth, though Ingenix margins compressed due to goodwill amortization.
  7. Ongoing litigation (ERISA/RICO class actions, MDL 1334) and government audits pose risk, though management does not expect a material adverse effect.

03—Questions

Frequently Asked Questions

  1. What drove UnitedHealth Group's earnings growth in 2000?

    Earnings from operations rose 27% to $1.2 billion. The main drivers were premium yield increases on UnitedHealthcare's commercial business, a lower commercial medical care ratio, and productivity gains that cut operating costs to 16.7% of revenue from 17.1%. Growth in Uniprise, Specialized Care Services and Ingenix also contributed.

  2. How much of 2000 net earnings came from one-time items?

    Net earnings of $736 million included a $14 million nonrecurring tax benefit tied to UnitedHealth Capital investments contributed to the UnitedHealth Foundation and a $27 million pre-tax gain ($17 million after tax) from a separate disposition. Excluding these, net earnings were $705 million, or $2.10 per diluted share.

  3. What are the main risks to UnitedHealth's profitability?

    Medical costs are largely priced in advance on an annual basis, and the company's narrow health plan margins mean small changes in the medical care ratio can significantly affect results. Other risks include heavy regulation of Medicare, Medicaid and FEHBP, pending class action litigation alleging ERISA and RICO violations, dependence on the AARP contract (about $3.5 billion in annual premium), and continued Medicare losses in some markets.

  4. How strong is the company's balance sheet and liquidity?

    Cash and investments totaled $5.1 billion at year-end, of which about $4.7 billion sits in regulated subsidiaries. Debt rose to $1.2 billion after a $400 million 7.5% note issuance, and the company is rated A by S&P and Fitch and A3 by Moody's. Shareholders' equity fell to $3.7 billion from $3.9 billion because of buybacks, despite strong earnings.

04—Continue

← View all 10-K filings